Innovative and transformative pre-clinical, translational, and clinical research, that has the potential to immediately impact the lives of Ewing’s sarcoma patients.
The Charlie Landers Foundation invites both new and established researchers to apply.
Applicants must have their MD, PhD, or dual MD PhD.
Established researchers should detail how their project differs from previously sponsored studies when requesting funding.
The application must distinctly show that new funding will not duplicate existing support.
New projects may be an extension of existing work but cannot overlap any sponsored studies.
Funds must be granted to nonprofit institutions or organizations operating in the U.S.
Researchers need not be United States citizens.
Grants range from $20,000-$150000 with a period of performance of one year.
An interim progress report will be required approximately six months following the start date of the award, and a final progress report will be due one month following the end date of the award.
If sufficient progress has been demonstrated, the awardee will have the option of a second year of funding with an additional $20,000-$150,000 if approved by the medical advisory board.
Indirect costs are not permitted.
Budget items may include salary, fringe, travel, supplies and small pieces of equipment (less than $10,000).
All proposals must be combined into a single PDF and submitted via the form at the bottom of this page.
Application Deadline: 1/26/2024
Announcement of Recipient: 3/28/24
Start of Grant: July 1, 2024
Questions regarding applications should be directed to: email@example.com
The Charlie Landers Foundation is committed to improving the prognosis and quality of life for those affected by Ewing’s sarcoma by funding groundbreaking research, offering direct patient support, and raising awareness about this rare and underfunded form of pediatric cancer.
In our first year we allocated over $350k to four high impact grants in the ongoing search of a cure. Our next fundraising target is to raise $400,000 for our 2024 grant cycle.